Sep 20, 2022 12:01 pm EDT Know Labs, Inc. Announces Closing of $8.28 Million Public Offering of Common Stock
Sep 15, 2022 6:02 pm EDT Know Labs, Inc. Announces Pricing of Upsized $7.2 Million Public Offering of Common Stock and Uplisting to the NYSE American Exchange
Sep 02, 2022 9:00 am EDT Know Labs Provides Update on IRB-Approved Internal Trial of Non-Invasive Glucose Monitoring Technology
Aug 03, 2022 9:00 am EDT Know Labs Files S-1 for New Share Offering, Seeks Uplist to NYSE American Exchange
May 24, 2022 9:00 am EDT Know Labs Expands Leadership Team, Adds Chief Financial Officer and Chief Product Officer, As It Gets Closer to FDA Clearance Application
Apr 05, 2022 9:00 am EDT New Foundational Patents Secure Multiple Growth Opportunities for Know Labs and Its Bio-RFID™ Non-Invasive Diagnostic Technology
Mar 08, 2022 9:00 am EST Know Labs Provides 2022 Outlook, Outlines Preparations for Pre-Submission Meeting with FDA
Feb 03, 2022 9:00 am EST Know Labs Receives IRB Approval to Begin Internal Clinical Trial of Non-Invasive Glucose Monitoring Technology Bio-RFID™